Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia
Study Details
Study Description
Brief Summary
Based on the investigator's previous data on risk classification for acute leukemia,the investigators will design a set of panels to detect the gene expression and genomic variants (SNPs, mutation, insertion, deletion and fusion genes, etc), and identify the high-risk subtypes of acute leukemia, such as Ph-like acute lymphoblastic leukemia. Furthermore, the target therapy (Tyrosine Kinase Inhibitors,et.al) will be used to treat the identified patients. In addition, more sensitive minimal residual disease (MRD) detection technology will be designed and used to detect the MRD in patients to early predict the disease relapse.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
patient eligibility criteria: newly diagnosed acute leukemia patients with clinical high-risk markers, reflactory and relapsed patients.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
high-risk group Selected by "High-risk subtype detection panels" |
Diagnostic Test: High-risk subtype detection panels
The designed detection technology were used to identify the high-risk patients cohort.
|
non high-risk group Selected by "High-risk subtype detection panels" |
Diagnostic Test: High-risk subtype detection panels
The designed detection technology were used to identify the high-risk patients cohort.
|
Outcome Measures
Primary Outcome Measures
- complete remission [From date of randomization or initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]
Patients achieve complete remission after initial treatment
- relapse [From date of randomization or complete remission until the date of first documented relapse from any cause, whichever came first, assessed up to 100 weeks]
Patients' disease progress after complete remission
Eligibility Criteria
Criteria
Inclusion Criteria:
- Newly diagnostic acute lymphoblastic leukemia Be willing to start treatment
Exclusion Criteria:
- chronic leukemia
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University | Nanjing | Jiangsu | China | 210009 |
Sponsors and Collaborators
- Zhongda Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZDYYGZ201708